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OBJECTIVES Studies were conducted to: 1) assess physicians’ attitudes and practices in managing
cardiovascular disease (CVD) risks in diabetes; and 2) determine the awareness of CVD risks
among diabetic patients.
BACKGROUND Cardiovascular disease is the leading cause of premature death among diabetic patients. As
diabetes is often seen as a “glucose-centric” disease, it is unclear whether diabetic patients are
talking with their doctors about CVD and other key clinical parameters of diabetes care such
as blood pressure and cholesterol.
METHODS An online survey was completed by a nationally representative sample of 900 physicians. The
95% confidence interval is approximately 2.5%. Before this study, a telephone survey of
2,008 people with diabetes was conducted using random, direct-dial screenings of U.S.
households.
RESULTS Ninety-one percent of physicians believe that their patients with diabetes are “very” or
“extremely” likely to have a cardiovascular event. Although physicians report discussing CVD
risk factors with 88% of their diabetic patients, they perceive their diabetic patients as being
only moderately knowledgeable about their increased CVD risks. Sixty-eight percent of the
people with diabetes do not consider CVD to be a serious complication of diabetes; they are
more likely to be aware of complications such as blindness (65%) or amputation (36%) rather
than heart disease (17%), heart attack (14%), or stroke (5%). Physicians perceive “poor
compliance” with behavioral modifications and medication regimens as the greatest barriers
to the management of CVD risks in diabetic patients.
CONCLUSIONS Materials should be made available to help facilitate communication about CVD risks, and
strategies for improving compliance with life-style modifications and multiple drug therapies
should be explored. Efforts should continue to promote a comprehensive approach to the
management of diabetes to include aggressive control of blood glucose and other CVD risk
factors. (J Am Coll Cardiol 2002;40:1877–81) © 2002 by the American College of
Cardiology Foundation
Cardiovascular disease (CVD) is a major complication and
the leading cause of premature death among people with
diabetes. Adults with diabetes are two to four times more
likely to have heart disease or suffer a stroke than people
without diabetes. Cardiovascular disease claimed more than
$7 billion of the $44.1 billion annual direct medical costs for
diabetes in 1997, the most costly of all complications of type
II diabetes (1).
While our nation has seen overall decreases in mortality
due to CVD over the past 30 years, people with diabetes
have not benefited from this decline. In fact, deaths due to
CVD in women with diabetes have increased (2). Results
from a recent study showing that the prevalence of diabetes
has increased by 49% from 1990 to 2000 are also troubling,
and projections indicate an increase of 165% by the year
2050 (3). The diabetes epidemic underscores an urgent need
for strategies to prevent CVD in people with diabetes.
To help reduce the morbidity and mortality associated
with diabetic CVD, the American Diabetes Association
(ADA) and the American College of Cardiology (ACC)
recently launched an initiative called “Make the Link!
Diabetes, Heart Disease and Stroke.” The initiative’s goals
are to increase public awareness of CVD and diabetes, to
decrease the incidence of CVD associated with diabetes, to
educate health care providers about proper CVD diagnosis
and treatment, and to inform patients of their risk and
appropriate therapies.
As part of this initiative, the two organizations commis-
sioned a survey to assess physicians’ attitudes and practices
in managing cardiovascular risk factors in patients with
diabetes. The survey obtained baseline data on how seriously
physicians view the cardiovascular risks of diabetes, how
they discuss these risks with their patients, and what they
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believe are the most significant barriers to the effective
management these risks. Before this survey, a study of
people with diabetes was performed to determine how much
they knew about their increased risks of CVD and whether
they were talking with their doctor about these risks. This
report provides a summary of the findings and discusses
implications for clinical care.
Survey methodologies. The physician survey was per-
formed on a representative national sample of approximately
700 primary-care physicians, 100 cardiologists, and 100
endocrinologists. It was fielded online by a marketing
information services company (TargetRx) in March 2002.
The survey of 2,008 people with diagnosed diabetes was
conducted during the August to October 2001 period by the
market research firm RoperASW, using random, direct-dial
screenings of U.S. households. The results were weighted
and projected to match the U.S.-diagnosed patient popula-
tion of 10.7 million based on an extrapolation of estimates
provided by the National Center for Health Statistics and
Centers for Disease Control and Prevention (CDC).
Key findings—physicians’ attitudes and practices.
Results from the physician survey indicate a high level of
awareness among physicians about the CVD risks associated
with diabetes. Ninety-one percent of the physicians believe
that their patients with diabetes are “very” or “extremely”
likely to have a cardiovascular event. This proportion is
higher than that for any other CVD risk factor (Fig. 1),
indicating that physicians recognize the extraordinary risk
associated with diabetes.
When asked to prioritize the treatment of blood glucose,
blood pressure, and low-density lipoprotein cholesterol,
63% of the physicians ranked the lowering of blood glucose
as the highest treatment priority for reducing CVD risks in
their patients with diabetes, with only 22% indicating that
blood pressure treatment was the highest priority and only
7% identifying cholesterol management as the highest
priority. When other factors such as smoking cessation and
aspirin therapy were included, control of blood glucose
remained the highest treatment priority for the majority of
physicians (Fig. 2).
Physicians perceive “poor compliance” with behavioral
modifications and complex medication regimens as the two
greatest barriers to the effective management of CVD risks
in patients with diabetes. Only 24% of the physicians
reported a lack of time to effectively counsel patients as
being a barrier (Table 1).
Physicians perceive that diabetic patients are significantly
less likely than non-diabetic patients with CVD to have met
treatment goals for blood pressure and lipids. Physicians
reported that they discussed the management of cardiovascular
risk factors with 88% of their diabetic patients, and almost all
physicians (95%) reported that they initiated these discussions.
However, physicians believe their patients with diabetes
Abbreviations and Acronyms
ADA  American Diabetes Association
ACC  American College of Cardiology
CDC  Centers for Disease Control and Prevention
CVD  cardiovascular disease
Figure 1. Association of conditions or attributes with physicians’ perception of the risk for a cardiovascular event. HDL high-density lipoprotein; LDL 
low-density lipoprotein.
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are only moderately knowledgeable of their increased risk of
a cardiovascular event. Primary-care physicians and endo-
crinologists believe that their patients with diabetes perceive
amputation and blindness as being their greatest risks.
Conversely, cardiologists report that the greatest risk as
perceived by diabetic patients is heart attack, perhaps
because diabetic patients in the care of cardiologists are
likely to have already experienced cardiovascular complica-
tions.
Key findings—patient awareness of cardiovascular risks.
These queries of individuals with diabetes showed that more
than two-thirds do not consider CVD to be a serious
complication of diabetes. People with diabetes are more
likely to be aware that diabetes may cause disabilities such as
blindness (65%) or amputation (36%) than they are that
diabetes may result in premature death from heart disease
(17%), heart attack (14%), or stroke (5%). Awareness of
CVD risks is lower among older adults and Hispanics,
Figure 2. Treatment prioritization by physicians to reduce risk of cardiovascular disease (CVD) events (diabetic vs. non-diabetic patients with CVD risk
factors). ACE  angiotensin-converting enzyme; LDL  low-density lipoprotein.
Table 1. Physician Perceptions of the Barriers of Care in Managing Cardiovascular Disease Risk
in Patients With Diabetes*
Greatest
Barrier
(%)
Second Greatest
Barrier
(%)
Third Greatest
Barrier
(%)
Total for Three
Greatest Barriers
(%)
Poor compliance with behavioral
modification recommendations
56 21 9 86
Poor compliance with multiple
medication regimens
18 38 21 77
Cost/lack of reimbursement 12 14 23 49
Lack of patient awareness of
CVD-related risks
5 10 17 33
Lack of time to sufficiently
counsel patients
5 7 12 24
Side effects of medications 1 5 13 19
Lack of efficacy of available
treatment options
2 4 4 10
Lack of physician identification
of CVD risk factors
1 1 1 3
*From the American Diabetes Association/American College of Cardiology survey of 900 physicians, conducted by TargetRx
in March 2002.
CVD  cardiovascular disease.
1879JACC Vol. 40, No. 10, 2002 Bairey Merz et al.
November 20, 2002:1877–81 Assessing the Cardiovascular Risks of Diabetes
three-fourths of whom do not name any cardiovascular
condition as a serious complication of diabetes.
According to the survey, the perception of personal
cardiovascular risk is low. More than half of the people with
diabetes do not feel at risk for a heart condition (52%) or
stroke (53%). Nearly two-thirds (60%) do not feel at risk of
either high blood pressure or high cholesterol.
People65 years of age with diabetes feel the least at risk
for CVD. Of these older adults, 65% do not feel at risk for
a heart condition; 61% do not feel at risk for stroke, and
nearly 70% feel little or no risk of high cholesterol or high
blood pressure.
Few people with diabetes could name important methods
of reducing their risk of heart attack or stroke, such as taking
prescription medications (18%), lowering cholesterol (8%),
quitting smoking (7%), reducing blood pressure (5%), and
taking aspirin (1%). Sixteen percent of the survey respon-
dents could not name any way to reduce their CVD risk.
People with diabetes report seeing their health care
provider about five times a year, and almost 75% say they
ask questions about managing their diabetes. Two-thirds of
the people with diabetes report discussing blood sugar
control at some or every visit. About half report that their
health care provider never discussed lowering blood pressure
(52%) or lowering cholesterol (45%).
Among smokers, more than one-third said quitting
smoking was not discussed.
Conclusions. The results of the physician and patient
surveys demonstrate a crucial need to improve communica-
tion between physicians and their patients about the link
between diabetes and CVD.
Although there is a high level of awareness among
physicians about the CVD risks associated with diabetes,
patients with diabetes have limited knowledge of these risks.
Cardiovascular disease is the leading cause of diabetes-
related deaths, but the majority of people with diabetes are
more fearful of complications such as blindness and ampu-
tation. Although three-quarters of patients surveyed self-
reported a cardiovascular complication such as high blood
pressure, high cholesterol, or stroke, they failed to link these
problems with their diabetes.
Physicians say they are talking to their patients about
their increased risk of cardiovascular complications, but
those warnings do not seem to be resonating with the
affected patient population. We may need to investigate and
better understand what is happening. Are people with
diabetes “hearing” about blood pressure and cholesterol but
not linking these conditions to their diabetes? Do people
with diabetes consider these to be separate diseases?
Diabetes is a complex disease that requires continuing
medical care and life-long patient education. The survey
results repeatedly reinforce this complexity and highlight
treatment compliance challenges associated with behavioral
changes and multiple medication regimens. The physicians’
belief that diabetic patients are less likely to meet treatment
goals than non-diabetic patients with CVD further under-
scores the difficulty in managing diabetes-related cardiovas-
cular risk factors. The effort required to self-manage diabe-
tes on a daily basis may also negatively impact one’s ability
to effectively treat other risk factors such as high blood
pressure and cholesterol. Strategies for improving patient
compliance with life-style modifications and multiple drug
therapies should be explored.
The majority of physicians surveyed identified the low-
ering of blood glucose as their highest priority in the effort
to reduce cardiovascular events in patients with diabetes.
Although a focus on glucose control is important in mini-
mizing the risk of microvascular complications, many would
argue that—because there are no definitive clinical trial data
demonstrating that intensified glycemic control significantly
reduces the risk of CVD—control of blood pressure and
lipids, smoking cessation, and the use of aspirin may be
more important in reducing life-threatening cardiovascular
complications. In fact, the CDC’s Cost-Effectiveness
Group recently published an analysis suggesting that inten-
sified blood pressure control would be a viable cost-saving
measure (4). The ADA recommends a comprehensive
approach to the management of diabetes that includes
aggressive management of cardiovascular risk. Table 2
includes a summary of key clinical goals (5).
Physicians agree that materials intended to educate dia-
betic patients about their cardiovascular risks would be
valuable tools to help them improve their patients’ knowl-
edge of the subject. To that point, the ADA and ACC,
through the “Make the Link!” initiative, will continue to
develop, distribute, and promote tools to help facilitate the
improvement of discussions between health care providers
and diabetic patients.
There is much we can do. Health care providers need to
talk with their patients more about the increased risk of a
heart attack or stroke, with the message that risk reduction
is possible. We need to stress that managing diabetes is
more than managing just blood glucose. Rather, it is
Table 2. Clinical Goals of the American Diabetes Association*
Key Clinical Goals
A1C 7%
Blood pressure 130/80 mm Hg
Lipid profile
Cholesterol 200 mg/dl
LDL cholesterol 100 mg/dl
HDL cholesterol 45 mg/dl (men) and 55 mg/dl (women)
Triglycerides 150 mg/dl
Others Stop smoking
Take aspirin, 81 to 325 mg/day (over age 21 years)
Consider ACE inhibitors for diabetic patients 55
years of age with at least one other CVD risk
factor to reduce risk of CVD events
*Source: American Diabetes Association. Standards of medical care for patients with
diabetes mellitus. Diabetes Care 2002;25 Suppl 1:S33–49. The full text of the
American Diabetes Association’s clinical practice recommendations is available online
at www.diabetes.org.
A1C  hemoglobin A1c; ACE  angiotensin-converting enzyme; CVD 
cardiovascular disease; HDL and LDL  high- and low-density lipoprotein,
respectively.
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managing the ABCs of diabetes: A1C, Blood pressure, and
Cholesterol. We need to refer our patients to appropriate
resources so that they get the education and support they
need. Once we help our patients make the link between
diabetes and CVD and empower them to take action, the
outcomes of their diabetes are likely to improve.
Reprint requests and correspondence: Gwen Twillman, Amer-
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APPENDIX
National Advisory Board for Diabetes: Eli Lilly & Co.;
Takeda Pharmaceuticals America, Inc.; Cyngus; TheraSense;
Amylin Pharmaceuticals; Aventis Pharmaceuticals; and Novo
Nordisk. All were contracted directly through the University of
North Carolina.
Consultancies: Amylin Pharmaceuticals; Eli Lilly & Co.;
Fujisawa Research Institute of America, Inc.; Insulet Corp.;
Instrumentation Metrics, Inc.; Novartis Pharmaceuticals;
Takeda Pharmaceuticals America, Inc.; and TheraSense. All
were contracted directly through the University of North
Carolina.
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